

# Phase I trial: CA47303

<b>Submission date</b> 08/04/2025	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/04/2025	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 10/04/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Dr Nadine Abdullah

### ORCID ID

<https://orcid.org/0000-0001-7772-7724>

### Contact details

22-24 Lisburn Road  
Belfast  
United Kingdom  
BT9 6AD  
+44 2890 554040  
[nadine.abdullah@celerion.com](mailto:nadine.abdullah@celerion.com)

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

1011728

### ClinicalTrials.gov (NCT)

Nil known

**Protocol serial number**

CA47303

## Study information

**Scientific Title**

Phase I trial: CA47303

**Study objectives**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

1. approved 02/04/2025, East of England - Cambridge East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, United Kingdom; +44 207 104 8096; cambridgeeast.rec@hra.nhs.uk), ref: IRAS ID 1011728

2. approved 02/04/2025, MHRA (10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 2030806000; info@mhra.gov.uk), ref: IRAS ID 1011728

**Study design**

Relative Bioavailability study in 20 healthy adult female volunteers

**Primary study design**

Interventional

**Study type(s)**

Other

**Health condition(s) or problem(s) studied**

Healthy volunteers

**Interventions**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Intervention Type**

Drug

**Phase**

Phase I

**Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Completion date**

14/05/2025

## **Eligibility**

**Key inclusion criteria**

Healthy human volunteer

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

45 years

**Sex**

Female

**Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Date of first enrolment**

16/04/2025

**Date of final enrolment**

18/04/2025

## Locations

### Countries of recruitment

United Kingdom

Northern Ireland

### Study participating centre

Celerion GB Ltd

22-24 Lisburn Road

Belfast

United Kingdom

BT9 6AD

## Sponsor information

### Organisation

Millicent Puerto Rico LLC

## Funder(s)

### Funder type

Industry

### Funder Name

Millicent Puerto Rico LLC

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

